Researchers Study Improvement in Patient Compliance and Screening Efficacy by Using the EyeArt AI Eye Screening System for Detecting Diabetic Retinopathy

The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half-million patient visits globally with over 2 million images collected in real-world clinical environments.

4/25/19: Results From Prospective, Multi-Center, Pivotal Clinical Trial on the EyeArt® AI Eye Screening System to be Announced by Eyenuk Inc. at the ARVO Conference

Eyenuk Inc. will showcase its EyeArt® AI Eye Screening System for autonomous detection of DR at Booth #1637 at the Vancouver Convention Centre Exhibition Hall. In addition, key management team members will be available to meet with researchers, clinicians and potential industry partners during the ARVO annual meeting.

Eyenuk, Inc. Receives Health Canada Approval for EyeArt™, an AI-enabled Cloud-based Automated Diabetic Retinopathy Screening Software

3/8/18: Eyenuk’s quality management system has been registered under the Medical Device Single Audit Program ("MDSAP") as conforming to the requirements of ISO 13485:2003, after successfully completing an audit for the relevant quality management system requirements of the U.S. Food and Drug Administration and Health Canada.